PT Medela Potentia Tbk (MDLA) Fair Value & Analysis
Healthcare · ID · Market cap 2.9T IDR
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 26 days ago
Share price +2.9% over the past month.
Below-average quality, screening 110% undervalued on our models.
What matters now
- The price is below even our cautious bear case (293.96 IDR). The market is more pessimistic than our downside scenario.
- Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (293.96 IDR to 594.86 IDR) leaves room in how you read the outcome.
Price vs Fair Value (16 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
16‑month range 166.83 IDR – 274.14 IDR · fair‑value band 293.96 IDR – 594.86 IDR · the 210.00 IDR price screens below the 440.09 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
PT Medela Potentia Tbk (MDLA) currently trades at 210.00 IDR, while our model-based Fair Value estimate is 440.09 IDR, implying the stock looks roughly 109.6% undervalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Medela Potentia Tbk generated revenue of 15.0T IDR at a net margin of 2.7%. Revenue grew 3.4% year over year. It earns a return on equity of 15.0%. The balance sheet holds a net cash position of 613B IDR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 293.96 IDR (bear case) to 594.86 IDR (bull case); at 210.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 110%, MDLA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Multiples (510.45 IDR) versus Asset-Based (145.15 IDR). Highest evidence: Growth DCF (80).
Notify me when MDLA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Medela Potentia Tbk distributes and markets pharmaceutical and healthcare products, and medical devices in Indonesia and Cambodia. It also manufactures medical devices, including consumables and medical equipment for hospitals and laboratories.
Full company description
PT Medela Potentia Tbk distributes and markets pharmaceutical and healthcare products, and medical devices in Indonesia and Cambodia. It also manufactures medical devices, including consumables and medical equipment for hospitals and laboratories. The company also processes medical device products; and digital platform and web portal activities for human use, as well as pharmaceutical products. In addition, the company develops GoApotik, a B2B2C platform for expanding its products to retailers, end consumers, and patients. PT Medela Potentia Tbk was founded in 2011 and is headquartered in Jakarta Selatan, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Medela Potentia Tbk reported revenue of 14.9T IDR in FY2025 versus 11.6T IDR in FY2021, a compound +6.4%/yr. Reported net income was 392B IDR in FY2025, compounding +4.8%/yr from FY2021.
Watch MDLA: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare PT Medela Potentia Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Medela Potentia Tbk (MDLA) overvalued or undervalued?
What is the fair value of MDLA?
What is the quality score of MDLA?
What is the revenue of PT Medela Potentia Tbk (MDLA)?
What is the net profit margin of MDLA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Medela Potentia Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.